About Us

Telix Pharmaceuticals was created to deliver on the promise of nuclear medicine


The field of nuclear medicine has historically lacked clinical momentum and commitment to late-stage product development. Our goal is to rectify this for the benefit of patients.

Latest News


Telix Pharmaceuticals Submits New Drug Application to US FDA for Prostate Cancer Imaging Product

Melbourne (Australia) and Indianapolis (U.S.A.) – 24th September 2020. Telix Pharmaceuticals submits NDA to US FDA for TLX591-CDx (Kit for...


First Patients Dosed in Clinical Trial of Novel Lung and Ovarian Cancer Theranostic

Melbourne and Adelaide (Australia) – 21st September 2020. Telix announces first two patients dosed in phase I trial of lung...


Telix Pharmaceuticals Enters Strategic Collaboration with Varian Medical Systems for Advanced Prostate Imaging

Melbourne (Australia) and Palo Alto, CA (USA) – 3rd September 2020. Telix announces it has entered into a strategic collaboration...


Telix Pharmaceuticals and IRE Elit Enter Distribution Partnership for Prostate Cancer Imaging

Herstal and Fleurus (Belgium) – 1st September 2020. Telix announces distribution agreement with Fleurus-based IRE Elit S.A. to distribute Telix’s...